01 / 20

Nucleotide Biosynthesis
De Novo & Salvage Pathways

Explore how cells build nucleotides from scratch and recycle them: the two essential strategies powering DNA replication, RNA synthesis, and energy metabolism.

Biochemistry

What Are Nucleotides?

Nucleotides are the monomeric building blocks of nucleic acids (DNA and RNA). Each nucleotide consists of three components joined together in a specific arrangement.

Nitrogenous Base
Purine (adenine, guanine) or pyrimidine (cytosine, uracil, thymine): encodes genetic information
Pentose Sugar
Ribose (RNA) or deoxyribose (DNA): forms the backbone scaffold
Phosphate Group(s)
One to three phosphate groups: drive energy transfer and polymerization

Purines vs. Pyrimidines

Purine (Double Ring) N N Adenine (A) Guanine (G) 9 atoms in ring system Built on ribose-5-phosphate Ring assembled ON the sugar Pyrimidine (Single Ring) N Cytosine (C) Uracil (U) / Thymine (T) 6 atoms in ring system Ring built first as free base Then attached to sugar

Why Do Cells Need Two Pathways?

Cells face a fundamental resource management challenge: building nucleotides from scratch is expensive but provides complete control, while recycling is efficient but depends on available materials. Most tissues use both strategies simultaneously.

De Novo Pathway
Builds nucleotides from simple precursors (amino acids, \(\text{CO}_2\), \(\text{NH}_3\)). Dominant in rapidly dividing cells like bone marrow and embryonic tissue.
Salvage Pathway
Recycles free bases and nucleosides from nucleic acid turnover. Energy-efficient and critical in brain, erythrocytes, and non-dividing tissues.

De Novo Purine Synthesis

Origin of Purine Ring Atoms N1
\(\text{Aspartate}\)
 C2
\(\text{Formate (THF)}\)
 N3 C4 C5 C6
\(\text{CO}_2\)
 N7 C8
\(\text{Formate (THF)}\)
 N9
\(\text{Glycine}\)
(C4, C5, N7)
\(\text{Glutamine}\)
\(\text{Glutamine}\)
 (N3, N9) Ring is assembled one atom at a time on ribose-5-phosphate
First complete nucleotide: \(\text{IMP}\)
10 enzymatic steps • Requires 6 \(\text{ATP}\) equivalents
Rate-limiting enzyme: \(\text{PRPP}\) amidotransferase

De Novo Pyrimidine Synthesis

Carbamoyl Phosphate
\(\text{Gln} + \text{CO}_2\)
+ 2 \(\text{ATP}\)
\(\text{CPS II}\)
\(\text{ATCase}\)
Carbamoyl Aspartate
+ Aspartate
Dihydroorotate
Orotate (free base)
+ \(\text{PRPP}\)
\(\text{UMP}\) (first nucleotide)
 KEY DIFFERENCE: Ring built FIRST, sugar added LATER
6 enzymatic steps • Rate-limiting: \(\text{CPS II}\) (mammals) / \(\text{ATCase}\) (bacteria)

The \(\text{IMP}\) Branch Point

\(\text{IMP}\)
Adenylosuccinate
(+Asp, requires \(\text{GTP}\))
\(\text{AMP}\)
\(\text{XMP}\)
(+\(\text{NAD}^+\), oxidation)
\(\text{GMP}\)
(+Gln, requires \(\text{ATP}\))
(requires \(\text{GTP}\) energy)
 Reciprocal regulation

The Salvage Pathways

Salvage pathways recycle free bases and nucleosides released during normal nucleic acid turnover. They bypass the expensive multi-step de novo synthesis using just one or two enzymatic reactions.

Purine Salvage
Free base + \(\text{PRPP}\)
\(\text{HGPRT}\) / \(\text{APRT}\)
Nucleotide (\(\text{NMP}\))
\(\text{HGPRT}\): Hypoxanthine/Guanine
\(\text{APRT}\): Adenine
 Pyrimidine Salvage
Nucleoside + \(\text{ATP}\)
 Kinases
Nucleotide (\(\text{NMP}\))
 Thymidine kinase Uridine kinase
Both require \(\text{PRPP}\) or \(\text{ATP}\): much cheaper than de novo

De Novo vs. Salvage: Key Distinctions

Feature De Novo Salvage
Starting materials Amino acids, \(\text{CO}_2\), \(\text{NH}_3\), \(\text{PRPP}\) Pre-formed bases / nucleosides + \(\text{PRPP}\) or \(\text{ATP}\)
Energy cost High (multiple \(\text{ATP}\), \(\text{GTP}\)) Low (1 \(\text{PRPP}\) or 1 \(\text{ATP}\))
Number of steps 6-10 enzymatic steps 1-2 enzymatic steps
Primary tissues Liver, bone marrow, embryonic Brain, RBCs, most non-dividing cells
Rate-limiting enzyme \(\text{PRPP}\) amidotransferase (purine) / \(\text{CPS II}\) (pyrimidine) \(\text{HGPRT}\) (purine) / Kinases (pyrimidine)
Clinical defect Target of anticancer drugs (methotrexate, \(\text{5-FU}\)) Lesch-Nyhan (\(\text{HGPRT}\) deficiency)

Regulation of Nucleotide Synthesis

1
Feedback inhibition: End products (\(\text{AMP}\), \(\text{GMP}\), \(\text{UMP}\), \(\text{CMP}\)) inhibit the first committed step of their own pathway.
2
Cross-regulation (purines): \(\text{AMP}\) synthesis needs \(\text{GTP}\); \(\text{GMP}\) synthesis needs \(\text{ATP}\). Excess of one drives production of the other.
3
\(\text{PRPP}\) availability: \(\text{PRPP}\) synthetase is inhibited by purine nucleotides. Low \(\text{PRPP}\) slows both de novo and salvage pathways.
4
Ribonucleotide reductase (\(\text{RNR}\)): Controls the reduction of ribonucleotides to deoxyribonucleotides for DNA synthesis. Allosterically regulated by nucleotide pools.

\(\text{PRPP}\): The Central Metabolite

\(\text{PRPP}\)
Ribose-5-P + \(\text{ATP}\)
\(\text{PRPP}\) synthetase
De novo purine
De novo pyrimidine
Purine salvage
\(\text{NAD}^+\) / Histidine
Inhibited by: \(\text{AMP}\), \(\text{GMP}\), \(\text{IMP}\)

How to Approach Pathway Problems

1
Identify the base type: Is it a purine (A, G) or pyrimidine (C, U, T)? This determines which pathway applies.
2
Determine the context: Is the cell dividing rapidly (de novo dominates) or quiescent (salvage dominates)?
3
Trace the precursors: For purines, ring atoms come from glycine, glutamine, aspartate, \(\text{CO}_2\), and \(\text{THF}\)-carried \(\text{C}_1\) units. For pyrimidines, aspartate and carbamoyl phosphate.
4
Check regulation: Which nucleotide inhibits which enzyme? Remember reciprocal purine regulation and \(\text{PRPP}\) as the shared hub.
5
Consider clinical connections: Drug targets (methotrexate blocks \(\text{THF}\)), enzyme deficiencies (\(\text{HGPRT}\)), and disease states (gout, \(\text{SCID}\)).

Example: Lesch-Nyhan Syndrome

A patient has a complete deficiency of \(\text{HGPRT}\). Predict the biochemical consequences.

1
Identify the enzyme role: \(\text{HGPRT}\) salvages hypoxanthine and guanine by converting them to \(\text{IMP}\) and \(\text{GMP}\) using \(\text{PRPP}\).
2
Without \(\text{HGPRT}\): Free bases cannot be recycled. They are instead oxidized to uric acid by xanthine oxidase.
3
\(\text{PRPP}\) accumulates: Since salvage doesn't consume \(\text{PRPP}\), excess \(\text{PRPP}\) drives increased de novo synthesis, producing even more purines.
4
Result: Massive uric acid overproduction causes severe gout, kidney stones, and characteristic neurological symptoms (self-injury, intellectual disability).

Example: Methotrexate Mechanism

Methotrexate is used in cancer chemotherapy. Explain its mechanism in terms of nucleotide biosynthesis.

Folate (\(\text{DHF}\))
\(\text{DHFR}\)
\(\text{THF}\)
\(\text{C}_1\) units for
purine synth
\(\text{IMP}\)
Methotrexate
Inhibits \(\text{DHFR}\)
 ✕
\(\text{THF}\) also
needed for
\(\text{dUMP}\) to \(\text{dTMP}\)
 Result: blocks both purine synthesis AND thymidylate synthesis

Example: From \(\text{NDP}\) to \(\text{dNDP}\)

How does a cell convert ribonucleotides to deoxyribonucleotides for DNA synthesis?

\(\text{NDP}\)
(ribonucleoside
diphosphate)
\(\text{RNR}\)
\(\text{dNDP}\)
(deoxyribonucleoside
diphosphate)
 kinase
\(\text{dNTP}\)
for DNA pol
 Reducing power:
Thioredoxin
regen. by \(\text{NADPH}\)
Exception: \(\text{dTMP}\)
\(\text{dUMP}\) + \(\text{THF}\) via thymidylate synthase

Common Mistakes

✕ Confusing Ring Assembly Order
Purine ring is built on the sugar (\(\text{PRPP}\) first). Pyrimidine ring is assembled as a free base first, then attached to \(\text{PRPP}\). Many students reverse this.
✕ Mixing Up \(\text{HGPRT}\) and \(\text{APRT}\)
\(\text{HGPRT}\) salvages hypoxanthine and guanine. \(\text{APRT}\) salvages adenine only. Lesch-Nyhan involves \(\text{HGPRT}\), not \(\text{APRT}\).
✕ Forgetting \(\text{RNR}\) Specificity
\(\text{RNR}\) acts on \(\text{NDP}\)s (diphosphates), not \(\text{NTP}\)s or \(\text{NMP}\)s. Also, \(\text{dTMP}\) is made from \(\text{dUMP}\) by thymidylate synthase, not by \(\text{RNR}\).

Question 1 of 5

In de novo purine biosynthesis, the first complete nucleotide formed is:

Question 2 of 5

A deficiency in \(\text{HGPRT}\) (hypoxanthine-guanine phosphoribosyltransferase) would most directly cause:

Question 3 of 5

Which statement correctly distinguishes de novo purine from de novo pyrimidine synthesis?

Question 4 of 5

Methotrexate inhibits dihydrofolate reductase (\(\text{DHFR}\)). Which processes are directly impaired?

Question 5 of 5

Ribonucleotide reductase (\(\text{RNR}\)) converts \(\text{NDP}\)s to \(\text{dNDP}\)s. Which regulatory feature ensures balanced \(\text{dNTP}\) pools?